Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4502184 | 0.81 | CYP1A2 (0.39) | CYP1A2CYP1B1CYP1A1CYP2B6MTNR1A | |
| SCHEMBL4712951 | 0.77 | CYP1A2 (0.41) | CYP1A2CYP1B1CYP1A1CYP2B6MTNR1A | |
| SCHEMBL4510020 | 0.70 | CYP1A2 (0.40) | CYP1A2CYP1B1CYP1A1CYP2B6MTNR1A | |
| SCHEMBL4510164 | 0.68 | CYP1A2 (0.39) | CYP1A2CYP1B1CYP1A1PARP1CYP2B6 | |
| SCHEMBL4823014 | 0.64 | CYP1A2 (0.38) | CYP1A2CYP1B1CYP1A1CYP2B6MTNR1A | |
| SCHEMBL8404603 | 0.62 | CYP1A2 (0.50) | CYP1A2CYP1B1CYP1A1CYP2B6MTNR1A | |
| SCHEMBL12714874 | 0.60 | PARP1 (0.63) | PARP1 | |
| SCHEMBL14894795 | 0.60 | PARP1 (0.50) | PARP1 | |
| SCHEMBL27609102 | 0.60 | MTNR1A (0.43) | CYP1A2CYP1B1CYP1A1CYP2B6MTNR1A | |
| SCHEMBL22754800 | 0.59 | NPC1 (0.47) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495111-B2 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | WYETH (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495111-B2 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | WYETH (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495111-B2 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | WYETH (US) | 2009-02-24 | — | — | US | disclosed |
| US-20070149585-A1 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | WYETH (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149585-A1 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | WYETH (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149585-A1 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | WYETH (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149585-A1 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | HTR1A, HTR7, HTR3A | CYP1A2 605/4885CYP1B1 1209/4885CYP1A1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.